EyePoint Pharmaceuticals
480 Pleasant Street
Suite B300
Watertown
Massachusetts
02472
United States
Website: http://www.eyepointpharma.com/
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders.
160 articles about EyePoint Pharmaceuticals
-
EyePoint Pharmaceuticals Announces Updated Positive Interim Safety and Efficacy Data from Ongoing Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD
2/12/2022
EyePoint Pharmaceuticals, Inc. announced updated interim data from the "Durasert® and Vorolanib in Ophthalmology" Phase 1 clinical trial of EYP-1901, a bioerodible sustained delivery intravitreal anti-vascular endothelial growth factor treatment targeting wet age-related macular degeneration.
-
BioSpace Movers & Shakers, Jan. 14
1/14/2022
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
EyePoint Pharmaceuticals Appoints Michael C. Pine as Chief Corporate Development and Strategy Officer
1/10/2022
EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced the appointment of Michael C. Pine as Chief Corporate Development and Strategy Officer.
-
EyePoint Pharmaceuticals Announces 2022 Clinical Plans and Highlights Recent Corporate and Clinical Achievements
1/10/2022
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), today announced its 2022 clinical pipeline plans and highlighted recent corporate achievements driven by its lead pipeline candidate, EYP-1901, a potential six-month intravitreal treatment targeting wet age-related macular degeneration (wet AMD).
-
EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce Expanded U.S. Commercial Alliance for DEXYCU®
12/7/2021
EyePoint Pharmaceuticals, Inc. and ImprimisRx jointly announced the expansion of their commercial alliance in which ImprimisRx will assume responsibility for U.S. sales and marketing activities for DEXYCU® 9% for the treatment of post-operative inflammation following ocular surgery in the U.S.
-
EyePoint Pharmaceuticals Announces Closing of $115.4 Million Public Offering
11/19/2021
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), today announced the closing of the previously announced underwritten public offering of 5,122,273 shares of its common stock.
-
EyePoint Pharmaceuticals Announces Pricing of Public Offering - Nov 17, 2021
11/17/2021
EyePoint Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 4,027,273 shares of its common stock at a public offering price of $13.75 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 3,272,727 shares of its common stock at a price to the public of $13.74 per each pre-funded warrant.
-
EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock - Nov 16, 2021
11/16/2021
EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock.
-
EyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD
11/13/2021
EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, announced six-month interim data from the "Durasert® and Vorolanib in Ophthalmology" Phase 1 clinical trial of EYP-1901, a bioerodible sustained delivery intravitreal anti-vascular endothelial growth factor treatment targeting wet age-related macular degeneration.
-
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences - Nov 11, 2021
11/11/2021
EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will present at two upcoming virtual conferences:
-
EyePoint Pharmaceuticals to Host Conference Call Highlighting Interim Phase 1 Clinical Data from Ongoing DAVIO Trial of EYP-1901 for Wet AMD
11/5/2021
EyePoint Pharmaceuticals, Inc. today announced that management will host a conference call to highlight interim data from its ongoing Phase 1 DAVIO trial of EYP-1901 for the potential treatment of wet AMD on Saturday, November 13 at 12:00 P.M. ET/11:00 A.M. CST.
-
EyePoint Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments
11/3/2021
EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, announced financial results for the third quarter ended September 30, 2021 and highlighted recent corporate developments.
-
EyePoint Pharmaceuticals Appoints Jay S. Duker, M.D. as Chief Operating Officer
11/1/2021
EyePoint Pharmaceuticals, Inc. today announced the appointment of Jay S. Duker, M.D. as Chief Operating Officer (COO).
-
EyePoint Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 3, 2021
10/27/2021
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 3, 2021 to report its third quarter 2021 financial results and discuss recent business highlights.
-
Clinical Catch-Up: October 11-15
10/18/2021
It was yet another busy week for clinical trial announcements. Take a look. -
EyePoint Pharmaceuticals Presents Preliminary Safety Data from Phase 1 DAVIO Trial and YUTIQ® CALM Registry Study at American Society of Retina Specialists (ASRS) 39th Annual Meeting
10/12/2021
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced positive interim safety data from its Phase 1 clinical trial of EYP-1901.
-
EyePoint Pharmaceuticals to Present Data at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting
9/17/2021
EyePoint Pharmaceuticals, Inc. announced that a late-breaking abstract highlighting topline data for the Phase 1 DAVIO trial of EYP-1901 in wet AMD has been selected for presentation at the American Academy of Ophthalmology 2021 Annual Meeting to be held from November 12 – 15, 2021.
-
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences - Sep 07, 2021
9/7/2021
EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced that EyePoint Pharmaceuticals’ senior management team will present at the following four upcoming conferences.
-
EyePoint Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference
8/10/2021
EyePoint Pharmaceuticals, Inc. today announced that Nancy Lurker, Chief Executive Officer of EyePoint Pharmaceuticals, will present at the H.C. Wainwright Ophthalmology Virtual Conference being held on August 17, 2021.
-
EyePoint Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments
8/4/2021
EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced financial results for the second quarter ended June 30, 2021 and highlighted recent corporate developments.